DK1162993T3 - Anvendelse af CASB616-polypeptider og polynukleotider til cancerbehandling - Google Patents

Anvendelse af CASB616-polypeptider og polynukleotider til cancerbehandling

Info

Publication number
DK1162993T3
DK1162993T3 DK00907633T DK00907633T DK1162993T3 DK 1162993 T3 DK1162993 T3 DK 1162993T3 DK 00907633 T DK00907633 T DK 00907633T DK 00907633 T DK00907633 T DK 00907633T DK 1162993 T3 DK1162993 T3 DK 1162993T3
Authority
DK
Denmark
Prior art keywords
polynucleotides
cancer treatment
casb616
polypeptides
casb616 polypeptides
Prior art date
Application number
DK00907633T
Other languages
English (en)
Inventor
Y De Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905124.5A external-priority patent/GB9905124D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1162993T3 publication Critical patent/DK1162993T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
DK00907633T 1999-03-05 2000-02-28 Anvendelse af CASB616-polypeptider og polynukleotider til cancerbehandling DK1162993T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9905124.5A GB9905124D0 (en) 1999-03-05 1999-03-05 Novel compounds
PCT/EP2000/001587 WO2000053216A2 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
EP00907633A EP1162993B1 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment

Publications (1)

Publication Number Publication Date
DK1162993T3 true DK1162993T3 (da) 2005-06-20

Family

ID=32870683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00907633T DK1162993T3 (da) 1999-03-05 2000-02-28 Anvendelse af CASB616-polypeptider og polynukleotider til cancerbehandling

Country Status (2)

Country Link
DK (1) DK1162993T3 (da)
SI (1) SI1162993T1 (da)

Also Published As

Publication number Publication date
SI1162993T1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1109453T3 (da) Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme
DK1083889T3 (da) Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
FI20000863A0 (fi) Uusi hoitomenetelmä
DK1176964T3 (da) Brug af ET743 til behandling af cancer
IS6202A (is) Lyfjauppskriftir og aðferðir til að gefa morfín ínös
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
EP1176940A4 (en) TREATMENT FOR HARDENING THE FINGERNAILS